» Articles » PMID: 22797305

A Remarkably Simple Genome Underlies Highly Malignant Pediatric Rhabdoid Cancers

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2012 Jul 17
PMID 22797305
Citations 192
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is principally considered a genetic disease, and numerous mutations are thought essential to drive its growth. However, the existence of genomically stable cancers and the emergence of mutations in genes that encode chromatin remodelers raise the possibility that perturbation of chromatin structure and epigenetic regulation are capable of driving cancer formation. Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characterized by biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. We identified an extremely low rate of mutation, with loss of SMARCB1 being essentially the sole recurrent event. Indeed, in 2 of the cancers there were no other identified mutations. Our results demonstrate that high mutation rates are dispensable for the genesis of cancers driven by mutation of a chromatin remodeling complex. Consequently, cancer can be a remarkably genetically simple disease.

Citing Articles

Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers.

Perotti D, OSullivan M, Walz A, Davick J, Al-Saadi R, Benedetti D Nat Rev Urol. 2025; .

PMID: 39881003 DOI: 10.1038/s41585-024-00993-6.


SMARCB1-deficient malignant melanocytic uveal tumours: a new neural crest-derived tumour entity with SMARCB1-related germline predisposition.

Cyrta J, Masliah-Planchon J, Hoare O, Brillet R, Andrianteranagna M, Sohier P J Pathol. 2025; 265(3):357-371.

PMID: 39853675 PMC: 11794973. DOI: 10.1002/path.6390.


Progress Toward Epigenetic Targeted Therapies for Childhood Cancer.

Liapodimitri A, Tetens A, Craig-Schwartz J, Lunsford K, Skalitzky K, Koldobskiy M Cancers (Basel). 2025; 16(24.

PMID: 39766049 PMC: 11674401. DOI: 10.3390/cancers16244149.


Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors.

Kes M, Morales-Rodriguez F, Zaal E, de Souza T, Proost N, van de Ven M Cell Rep Med. 2024; 6(1):101878.

PMID: 39708810 PMC: 11866552. DOI: 10.1016/j.xcrm.2024.101878.


Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors.

Merk D, Tsiami F, Hirsch S, Walter B, Haeusser L, Maile J Genome Biol. 2024; 25(1):301.

PMID: 39617889 PMC: 11610224. DOI: 10.1186/s13059-024-03438-w.


References
1.
Roberts C, Leroux M, Fleming M, Orkin S . Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2002; 2(5):415-25. DOI: 10.1016/s1535-6108(02)00185-x. View

2.
Wilson B, Roberts C . SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011; 11(7):481-92. DOI: 10.1038/nrc3068. View

3.
Versteege I, Sevenet N, Lange J, Rousseau-Merck M, Ambros P, Handgretinger R . Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998; 394(6689):203-6. DOI: 10.1038/28212. View

4.
Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

5.
Roberts C, Biegel J . The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 2009; 8(5):412-6. PMC: 2709499. DOI: 10.4161/cbt.8.5.8019. View